WebNANJING, China, May 9, 2024 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Financing. The Series B+ was funded by Hyfinity Investments. 14 WebInxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma microenvironment and …
InxMed Releases Data Demonstrating IN10018 Therapeutic
Web电话： 025-58251030 邮箱： [email protected] 公司地址： 南京市江北新区探秘路73号树屋十六栋D-2栋3层 Web4 mrt. 2024 · InxMed Co., Ltd, a Nanjing, China-based clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma … implicit harvard association test
About_INMED (Wuxi) Medical Device Co., Ltd.
WebInxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma microenvironment and … WebDiscovery Company profile page for Inxmed (Nanjing) Co., Ltd including technical research,competitor monitor,market trends,company profile& stock symbol WebInxMed is a clinical-stage biotech company established in the end of 2024. The company dedicates on developing innovative therapies targeting stroma microenvironment and … literacy form time